Literature DB >> 12755905

Interactions of xylazine and detomidine with alpha2-adrenoceptors in brain tissue from cattle, swine and rats.

K Törneke1, U Bergström, A Neil.   

Abstract

Xylazine is an alpha2-adrenoceptor agonist sedative with a much higher interspecies variability in effect than detomidine, another alpha2-agonist used in veterinary practice. In the present study, we have used radioligand binding in brain tissue to investigate if the high species variation in sensitivity to xylazine could be explained in terms of receptor interactions. Species known to be more (cattle) or less (swine and rats) sensitive to xylazine were used. There was no variation in the density or the subtype pattern of the alpha2-adrenoceptors that could explain the species variation recorded in vivo, as a homogenous population of the alpha2A/D-subtype (200-300 fmol/mg protein) was found in all species. The species differences in the affinities of xylazine and detomidine were minor and similar for the two drugs. The only parameter investigated where a significant species difference was found for xylazine but not for detomidine was the slope of the inhibition binding curve when the G-protein coupling was diminished. For xylazine this slope was considerably lower than unity (i.e. 0.77 +/- 0.075) using cattle preparations compared with 0.92 +/- 0.037 (mean +/- SE) and 0.90 +/- 0.028, respectively for swine and rats, while for detomidine this parameter was close to unity in all species (cattle, swine, rat). This finding indicates that the species variation in effect for xylazine could be due to differences at the G-protein level or further down-stream in the effect cascade.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12755905     DOI: 10.1046/j.1365-2885.2003.00466.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  1 in total

1.  Plasma glucose concentration is maintained during TSE infection of cattle and sheep.

Authors:  R A Horton; G G Allison; D Jayasena; P Rees Stevens; D Clifford; S Everest; R Jackman; J M Moorby
Journal:  Vet Res Commun       Date:  2007-09-06       Impact factor: 2.459

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.